Psoriasis and Obesity

Jensen, Peter; Skov, Lone

doi:10.1159/000455840

Cited by 221 publications

(218 citation statements)

References 77 publications

Supporting

Mentioning

176

Contrasting

Unclassified

Order By: Relevance

“…Individual PASI scores in this study ranged from 0.7 to 34.8 and the upper end of the PASI scale (up to 72) was not encountered. Over 75% of study patients were overweight with a high mean BMI of 29.6 kg/m 2 , which confirms epidemiological evidence . The inter‐ and intraobserver variability of image‐based PASI measurements in our study was low.…”

Section: Discussionsupporting

confidence: 85%

Intra‐ and interobserver variability of image‐based PASI assessments in 120 patients suffering from plaque‐type psoriasis

Fink

Alt

Uhlmann

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 85%

Intra‐ and interobserver variability of image‐based PASI assessments in 120 patients suffering from plaque‐type psoriasis

Fink

Alt

Uhlmann

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence has indicated that psoriasis is clinically relevant to other systematic diseases, including Crohn's disease and obesity . The question that puzzles investigators regards the relationship and common features between psoriasis and those diseases.…”

Section: Introductionmentioning

confidence: 99%

The Akkermansia muciniphila is a gut microbiota signature in psoriasis

Tan

Zhao

Zhu

et al. 2018

Experimental Dermatology

163

149

View full text Add to dashboard Cite

Psoriasis is an immune-mediated chronic inflammatory skin disease. Although its pathogenesis is not fully understood, Th17 cells and the cytokines they produce, such as IL-17, IL-22 and IL-23, play critical roles in the pathogenesis of psoriasis. Evidence has demonstrated that psoriasis has some common features, including immune responses (due to Th17 cells) and inflammatory cytokine profiles, with systematic diseases including inflammatory bowel diseases (IBDs) and obesity. Recently, studies have demonstrated that the gut microbiota plays a crucial role in host homoeostasis and immune response, particular in Th17 cells, but the role of the gut microbiota in psoriasis remains unclear. To study the relationship between gut microbiota and psoriasis, we analysed microbiota profiles in psoriasis using a 16S rDNA sequencing platform, and we found that the abundance of Akkermansia muciniphila was significantly reduced in patients with psoriasis. A. muciniphila is believed to have an important function in the pathogenesis of IBD and obesity; therefore, A. muciniphila, which is an indicator of health status, may be a key node for psoriasis as well as IBD and obesity. Taken together, our study identified that gut microbiota signature and function are significantly altered in the gut of patients with psoriasis, which provides a novel angle to understanding the pathogenesis of psoriasis.

show abstract

“…Psoriasis is frequently associated with metabolic syndrome including obesity . Overweight and weight gain have been shown to be predictive for the development of psoriasis .…”

Section: Introductionmentioning

confidence: 99%

Effects of tumor necrosis factor‐α, interleukin‐23 and interleukin‐17A inhibitors on bodyweight and body mass index in patients with psoriasis

Takamura

Takahashi

Inoue

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Treatment with tumor necrosis factor-α inhibitors has been reported to cause weight gain in patients with psoriasis; however, limited information is available in terms of the effects of interleukin (IL)-23 and IL-17A inhibitors on bodyweight (BW) in patients with psoriasis. This study aimed to investigate the effects of infliximab, ustekinumab and secukinumab on BW and body mass index (BMI) in patients with psoriasis. We retrospectively examined changes in BW and BMI among patients treated with these biologics at our hospital. At baseline, no significant differences in BW and BMI were observed among the patients treated with infliximab (n = 18), ustekinumab (n = 30) or secukinumab (n = 20). After 7 months of the therapy, significant increases in mean BW (from 71.4 to 74.3 kg) and mean BMI (from 24.7 to 25.7) were observed in the patients treated with infliximab, whereas no significant changes were observed in those treated with ustekinumab (BW, from 70.3 to 70.1 kg; BMI, from 25.4 to 25.3) or secukinumab (BW, from 69.0 to 68.9 kg; BMI, from 25.2 to 25.2). There were no differences in the proportion of the patients who showed 75% or more improvement in the Psoriasis Area and Severity Index among the three groups. These results suggest that infliximab increases BW in the patients with psoriasis, whereas ustekinumab and secukinumab do not affect the BW in these patients.

show abstract

Psoriasis and Obesity

Cited by 221 publications

References 77 publications

Intra‐ and interobserver variability of image‐based PASI assessments in 120 patients suffering from plaque‐type psoriasis

Intra‐ and interobserver variability of image‐based PASI assessments in 120 patients suffering from plaque‐type psoriasis

The Akkermansia muciniphila is a gut microbiota signature in psoriasis

Effects of tumor necrosis factor‐α, interleukin‐23 and interleukin‐17A inhibitors on bodyweight and body mass index in patients with psoriasis

Contact Info

Product

Resources

About